Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease

Journal of the American Academy of Dermatology

Volumn 46, Issue 1, 2002, Pages 123-127

  Ulmer, Anja ^a   Kötter, Ina ^a   Pfaff, Andreas ^a   Fierlbeck, Gerhard ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIXED CONNECTIVE TISSUE DISEASE; PRIORITY JOURNAL; RASH; RISK BENEFIT ANALYSIS; SIDE EFFECT;

EID: 0036145436     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.118539     Document Type: Article

References (43)

1. Mixed connective tissue disease: An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)
2. Mixed connective tissue disease
3. Mixed connective tissue disease: Overrap syndromes
4. Dermatological uses of high-dose intravenous immunoglobulin
5. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis
6. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients
7. Treatment of dermatomyositis with intravenous gammaglobulin
8. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: An open study in 11 adult patients
9. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: Clinical responses and effect on slL-2R levels
10. A study of 20 SLE patients with intravenous immunoglobulin: Clinical and serologic response
11. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin
12. High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study
13. Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin
14. Long-term i.v. Ig treatment in systemic lupus erythematosus
15. Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus
16. Successful treatment of systemic lupus erythematosus with IgM-enriched immunoglobulins
17. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: Experience in six patients
18. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy
19. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris
20. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy
21. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins
22. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: A preliminary study
23. Epidermolysis bullosa acquisita: Efficacy of high-dose intravenous immunoglobulins
24. Efficacy of human intravenous immune globulin in pyoderma gangrenosum
25. Lupus anticoagulant and recurrent fetal loss: Successful treatment with gammaglobulin
26. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy
27. Gammaglobulin infusion therapy in a patient with antiphospholipid syndrome
28. Successful control of refractory and life-threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with the primary antiphospholipid syndrome
29. Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin
30. Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis
31. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: A report of three patients and review of the literature
32. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus
33. Immunoglobulin therapy in inflammatory myopathies
34. Childhood mixed connective tissue disease
35. Long-term outcome in mixed connective tissue disease: Longitudinal clinical and serologic findings
36. Severe thrombocytopenia and high-dosage intravenous gammaglobulin therapy in a patient with scleroderma-systemic lupus erythematodes overlap
37. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
38. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia
39. Renal toxicity of intravenous immunoglobulin
40. Acute renal failure resulting from intravenous immunoglobulin therapy
41. Aseptic meningitis as a side effect of intravenous immune gammaglobulin
42. Mechanisms of action of intravenous immune globulin in immune-mediated diseases
43. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin